Wall Street analysts expect that vTv Therapeutics Inc (NASDAQ:VTVT) will report ($0.11) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for vTv Therapeutics’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.16). vTv Therapeutics reported earnings per share of ($0.06) in the same quarter last year, which suggests a negative year-over-year growth rate of 83.3%. The company is scheduled to announce its next earnings results on Thursday, November 14th.

On average, analysts expect that vTv Therapeutics will report full year earnings of ($0.53) per share for the current fiscal year. For the next year, analysts forecast that the firm will report earnings of ($0.43) per share, with EPS estimates ranging from ($0.60) to ($0.25). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The business had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.63 million.

Several equities research analysts have recently weighed in on the company. ValuEngine lowered vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Northland Securities reissued a “buy” rating and issued a $8.00 target price on shares of vTv Therapeutics in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of vTv Therapeutics in a research report on Friday, August 16th. Finally, Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st.

VTVT traded up $0.09 during midday trading on Friday, reaching $1.47. 620,654 shares of the company’s stock were exchanged, compared to its average volume of 816,856. The business has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $1.56. The firm has a market capitalization of $73.62 million, a price-to-earnings ratio of -2.13 and a beta of -3.64. vTv Therapeutics has a one year low of $0.68 and a one year high of $6.09.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman bought 606,061 shares of vTv Therapeutics stock in a transaction dated Wednesday, September 4th. The shares were acquired at an average cost of $1.65 per share, with a total value of $1,000,000.65. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Ronald O. Perelman bought 50,000 shares of vTv Therapeutics stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average cost of $1.38 per share, for a total transaction of $69,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,442,424 shares of company stock worth $7,265,500. 1.70% of the stock is owned by insiders.

An institutional investor recently raised its position in vTv Therapeutics stock. BlackRock Inc. grew its holdings in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 65,031 shares of the biotechnology company’s stock after purchasing an additional 13,305 shares during the quarter. BlackRock Inc. owned about 0.12% of vTv Therapeutics worth $93,000 as of its most recent filing with the SEC. 1.64% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Article: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.